ClinicaliQ Trial Snapshot
- Neoadjuvant Darovasertib in Primary Uveal Melanoma — Recruiting • Phase III • Oncology • NCT07015190.
- What is being tested: Darovasertib, a PKC412 inhibitor, administered before surgery (neoadjuvant approach) in patients with primary uveal melanoma to assess efficacy in reducing metastatic recurrence and improving overall survival compared to standard surgical management alone.
- Patient eligibility overview: Adults with newly diagnosed, non-metastatic primary uveal melanoma who are candidates for surgical resection; trial excludes those with evidence of distant metastases or prior systemic therapy for this malignancy.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Eligibility Snapshot
- : * Primary non-metastatic uveal melanoma * Able and willing to provide written, informed consent before initiation of any study-related procedures, and in the opinion of the Investigator, to comply with all study requirements * ECOG 0 or 1 * Adequate organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.